Metabolic health encompasses several interrelated factors — blood sugar regulation, lipid balance, body weight, and inflammatory status. Disruptions in any of these areas can increase the risk of conditions such as type 2 diabetes, cardiovascular disease, and non-alcoholic fatty liver disease. A growing body of preclinical and clinical research has begun to examine whether specific functional mushrooms may support aspects of metabolic health, though most evidence remains preliminary and requires larger, well-controlled trials to confirm.
Blood Sugar and Insulin Sensitivity
Among the most studied mushrooms for metabolic effects is Grifola frondosa (maitake). A study published in Bioscience, Biotechnology, and Biochemistry found that lipid-soluble extracts of G. frondosa activated the peroxisome proliferator-activated receptor delta (PPARdelta) in vitro, and that oral administration to high-fat-diet-induced obese mice lowered total blood cholesterol levels and improved glucose intolerance.[1] PPARdelta is a nuclear receptor involved in fatty acid oxidation and glucose homeostasis, suggesting a possible mechanistic pathway. However, this work was conducted in animal models; human trials specifically examining maitake and insulin sensitivity are limited.
Research on white button mushrooms (Agaricus bisporus) in adults with metabolic syndrome found that 16 weeks of daily consumption was associated with significant increases in the antioxidant compound ergothioneine and the anti-inflammatory hormone adiponectin, as well as decreases in oxidative stress markers carboxymethyllysine and methylglyoxal — both implicated in the development of type 2 diabetes.[2] Notably, no statistically significant changes were observed in insulin resistance or glucose metabolism markers in this retrospective analysis, highlighting the complexity of translating antioxidant improvements to clinical glycemic outcomes. The authors called for well-controlled prospective trials before conclusions can be drawn.
Lipid Profiles and Cholesterol
Reishi (Ganoderma lucidum) has attracted research attention for potential effects on blood lipids. A randomized, double-blind, placebo-controlled crossover trial published in Nutrients in 2025 enrolled 110 participants with dyslipidemia and evaluated G. lucidum spore oil over 12 weeks.[3] The intervention group showed statistically significant reductions in total cholesterol, triglycerides, and LDL-cholesterol, alongside increases in HDL-cholesterol compared to the placebo group. Hepatic function parameters also improved in the intervention group. While these findings are notable given the randomized controlled design, replication in larger and more diverse populations would strengthen confidence in the results.
Enoki mushroom polysaccharides (Flammulina velutipes) have also been examined in the context of metabolic syndrome. A preclinical study in Food and Function demonstrated that oral administration of F. velutipes polysaccharide in high-fat-diet-fed mice attenuated obesity, hyperlipidemia, and insulin resistance, with effects mediated partly through modulation of gut microbiota composition and upregulation of lipid-metabolism genes including AMPK-alpha1 and PPAR-alpha.[4] As with many mushroom studies, these results come from animal models rather than human clinical trials, and extrapolating findings to human supplementation requires caution.
Triglycerides and Adipose Tissue
A study examining Grifola gargal — a less commonly studied medicinal mushroom — reported that 10 adults with prediabetes who consumed a low-molecular-weight hot water extract daily for four weeks experienced significant decreases in triglyceride levels.[5] This small human pilot was accompanied by animal data showing reductions in blood glucose, triglycerides, and adipose tissue in obese and diabetic mouse models. The study authors described these findings as a first-in-humans report and noted that larger trials are needed to assess efficacy and optimal intake parameters.
The Role of Beta-Glucans and Polysaccharides
Much of the metabolic research on functional mushrooms is attributed to their beta-glucan and polysaccharide fractions. Beta-glucans are soluble dietary fibers that may slow glucose absorption in the gut, reduce postprandial blood sugar responses, and support cholesterol elimination by binding bile acids. These mechanisms are not unique to mushrooms — beta-glucans from oats and barley are better characterized in human trials — but mushroom-derived polysaccharides appear to exert additional immunomodulatory and gut-microbiome-shaping effects that may indirectly influence metabolic parameters.
Researchers have also highlighted the potential role of ergothioneine, a unique antioxidant found at relatively high concentrations in several mushroom species. Oxidative stress and chronic low-grade inflammation are recognized contributors to insulin resistance and metabolic dysfunction, and compounds that attenuate these processes may play a supporting role in metabolic health management.
What the Evidence Cannot Yet Confirm
It is important to contextualize the current state of this research. The majority of mechanistic work has been performed in cell cultures or rodent models. Human trials, where they exist, are often small, short in duration, and use heterogeneous extract formulations that make direct comparisons difficult. No functional mushroom has been shown to replace standard-of-care interventions for diabetes, dyslipidemia, or metabolic syndrome. Statements that any mushroom “cures” or “reverses” metabolic disease are not supported by the available evidence.
For a broader overview of how specific mushrooms may interact with lipid metabolism, see our dedicated post on functional mushrooms and cholesterol.
Summary
Emerging preclinical and early clinical research suggests that certain functional mushrooms — including maitake, reishi, enoki, and white button mushrooms — may support aspects of metabolic health such as lipid profiles, oxidative stress markers, and potentially blood sugar regulation. The most robust human evidence to date involves reishi spore oil and its effects on lipid panels in a randomized controlled trial. Across all species, larger and more rigorous clinical studies are needed before firm conclusions can be drawn about efficacy, safety in specific populations, or appropriate use alongside conventional metabolic medications.
References
- [1] Aoki H, et al. Grifola frondosa (Maitake) extract activates PPARdelta and improves glucose intolerance in high-fat diet-induced obese mice. Biosci Biotechnol Biochem. 2018;82(9):1550-1559. PMID: 29873587
- [2] Calvo MS, et al. A Retrospective Study in Adults with Metabolic Syndrome: Diabetic Risk Factor Response to Daily Consumption of Agaricus bisporus. Plant Foods Hum Nutr. 2016;71(3):245-51. PMID: 27193019
- [3] Wang X, et al. Clinical Evaluation of Ganoderma lucidum Spore Oil for Triglyceride Reduction: A Randomized, Double-Blind, Crossover Study. Nutrients. 2025;17(5):844. PMID: 40077714
- [4] Zhao R, et al. Polysaccharide from Flammulina velutipes attenuates markers of metabolic syndrome by modulating the gut microbiota and lipid metabolism in high fat diet-fed mice. Food Funct. 2021;12(15):6964-6980. PMID: 34137411
- [5] Harada E, et al. Medicinal Mushroom, Grifola gargal (Agaricomycetes), Lowers Triglyceride in Animal Models of Obesity and Diabetes and in Adults with Prediabetes. Int J Med Mushrooms. 2020;22(1):79-91. PMID: 32464000
Disclaimer: This article is for informational purposes only and does not constitute medical advice. Functional mushrooms are not intended to diagnose, treat, cure, or prevent any disease. Consult a qualified healthcare provider before making changes to your diet or supplement regimen, particularly if you have a chronic condition or take prescription medications.
